LY 438434
Latest Information Update: 30 Jul 2002
Price :
$50 *
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action Somatotropin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Somatotropin deficiency
Most Recent Events
- 15 Sep 1999 Preclinical development for Somatotropin deficiency in USA (Unknown route)